Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis

BACKGROUND: The newer oral anticoagulant dabigatran is considered to be more beneficial in patients with non-valvular Atrial Fibrillation (AF) when compared to warfarin. However, because bleeding events which are associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran have seld...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundhun, Pravesh Kumar, Chaudhary, Nabin, Yuan, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353890/
https://www.ncbi.nlm.nih.gov/pubmed/28298191
http://dx.doi.org/10.1186/s12872-017-0511-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353890/
https://www.ncbi.nlm.nih.gov/pubmed/28298191
http://dx.doi.org/10.1186/s12872-017-0511-8

Ejemplares similares